AdvtBy ,ET PharmaJoin the community of 2M+ industry professionals.
Subscribe to Newsletter to get latest insights & analysis in your inbox.
All about ETPharma industry right on your smartphone!
Download the ETPharma App and get the Realtime updates and Save your favourite articles.
Mumbai: Drugmaker Lupin Limited posted net sales of Rs 7,100 crore, up 26.4 per cent against the year ago period, driven by a strong uptick in US sales.Ebitda for the quarter stood at Rs 2,376 crore while net profit jumped 37.4 per cent year-on-year (YoY) to Rs 1,180 crore.In Q3, Lupin sustained its growth momentum on a strong upswing in its US sales, which posted a 54 per cent YoY growth to Rs 3,113 crore.Revenue from emerging markets jumped 42.4 per cent to Rs 917 crore, whole other development markets revue expanded 10.8 per cent to Rs 812 crore.Meanwhile, sales in India remained subdued, registering a modest growth of 5.6 per cent to Rs 2,038 crore.Commenting on the Q3 FY26 results, Nilesh D Gupta, Managing Director, Lupin Limited said, “We are happy to deliver another quarter of strong growth, led by our highest ever quarterly sales in the U.S. and we are on track to deliver a strong close to FY26.”>